Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Oncology
• Urothelial Carcinomas
• Clinical Practice Guidelines

Background:

• Muscle-invasive urothelial bladder cancer requires effective systemic therapy.
• Previous NCCN Guidelines did not fully incorporate newer treatment options.
• Significant advancements in immunotherapy have emerged.

Purpose of the Study:

• To summarize key updates in the 2017 NCCN Clinical Practice Guidelines for Bladder Cancer.
• To highlight new recommendations for systemic therapy in muscle-invasive urothelial bladder cancer.
• To provide a focused overview of immunotherapy agents.

Main Methods:

• Review of the NCCN Clinical Practice Guidelines for Bladder Cancer (2017 edition).
• Focus on sections pertaining to systemic therapy for muscle-invasive urothelial bladder cancer.
• Identification of newly added agents and recommendations.

Main Results:

• The 2017 NCCN Guidelines include new recommendations for immunotherapy drugs: nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab.
• These agents represent significant additions to the systemic therapy landscape for muscle-invasive urothelial bladder cancer.
• The guidelines address the integration of these novel treatments.

Conclusions:

• The 2017 NCCN Guidelines reflect substantial progress in bladder cancer systemic therapy.
• New immunotherapy options offer expanded treatment choices for patients with muscle-invasive urothelial bladder cancer.
• Oncologists should consult the full guidelines for comprehensive management strategies.